Betul Oran, M.D.

Peer-Reviewed Articles

1. Ustun, C, Zhang, MJ, Peterson, A, Baek, A, Agha, ME, Alkhateeb, HB, Chhabra, S, Coltoff, A, De Lima, M, Gandhi, A, Ho, VT, Kassim, A, Lin, A, Gowda, L, Borthakur, G, DeAngelo, DJ, McGuirk, J, Mensah, F, Nadiminti, KV, Nishihori, T, Pantin, JM, Trunk, A, Uberti, JP, Marcucci, G, Gotlib, J, Akin, C, Hamadani, M, Pullarkat, V, Valent, P, Grunwald, MR, Juckett, M, Oran, B, Saber, W, Burns, LJ. Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era. British Journal of Haematology 207(6):2486-2495, 2025. e-Pub 2025. PMID: 40983528.
2. Mehta, RS, Aljawai, YM, Kebriaei, P, Olson, AL, Oran, B, Rondon, G, Rezvani, K, Champlin, RE, Shpall, E. The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy 31(11):920.e1-920.e14, 2025. e-Pub 2025. PMID: 40819683.
3. Aljawai, YM, Ramdial, JL, Smallbone, PI, Chen, GL, Kebriaei, P, Pasvolsky, O, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults. Blood Advances 9(20):5201-5206, 2025. e-Pub 2025. PMID: 40795211.
4. Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, Kadia, TM, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer 131(16), 2025. e-Pub 2025. PMID: 40782343.
5. Aljawai, YM, Ramdial, JL, Rondon, G, Smallbone, PI, Kebriaei, P, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis. Blood Advances 9(15):4023-4036, 2025. e-Pub 2025. PMID: 40517414.
6. Smallbone, PI, Shigle, TL, Paslovsky, O, Hosing, C, Alousi, AM, Bashir, Q, Aljawai, YM, Ramdial, JL, Popat, UR, Champlin, RE, Shpall, E, Oran, B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
7. Oran, B, Thall, PF, Alousi, AM, Al-Atrash, G, Mehta, RS, Marin, D, Kebriaei, P, Popat, UR, Bassett Jr, R, Bashir, Q, Im, JS, Olson, AL, Jewell, J, Smallbone, PI, Shpall, E, Champlin, RE. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant. Haematologica 111(1):149-157, 2025. e-Pub 2025. PMID: 40702903.
8. Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial JL, Chen GL, Kadia TM, Short NJ, Daver NG, Kantarjian HM, Marin D, Kebriaei P, Popat UR, Champlin RE, Shpall EJ, Oran B. TP53 Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation. Blood Adv 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
9. Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
10. Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
11. Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
12. Jain T, Estrada-Merly N, Salas MQ, Kim S, DeVos JD, Chen M, Fang X, Kumar R, Andrade-Campos M, Elmariah H, Agrawal V, Aljurf M, Bacher U, Badar T, Badawy SM, Ballen KK, Beitinjaneh A, Bhatt VR, Bredeson CN, DeFilipp Z, Dholaria B, Farhadfar N, Farhan S, Gandhi A, Ganguly S, Gergis U, Grunwald MR, Hamad N, Hamilton BK, Inamoto Y, Iqbal M, Jamy O, Juckett M, Kharfan-Dabaja MA, Krem MM, Lad DP, Liesveld JL, Al Malki MM, Malone AK, Murthy HS, Ortí G, Patel SS, Pawarode A, Perales MA, van der Poel MWM, Ringden O, Rizzieri DA, Rovo A, Savani BN, Savoie ML, Seo S, Solh MM, Ustun C, Verdonck LF, Wingard JR, Wirk B, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott BL, Saber W, Gupta V. Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study. Blood Adv 8(16):4281-4293, 2024. e-Pub 2024. PMID: 38916866.
13. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
14. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
15. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
16. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
17. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and outcomes of patients with multiple myeloma who developed therapy-related acute myeloid leukemia and myeloid leukemia and myelodysplastic syndrome following autologous cell transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
18. Oran E, Abo-Serie E, Jewkes J, Henry M, Oran B. Design and optimisation of an Intra-Aortic Shrouded rotor axial pump. J Biomech 162:111858, 2024. e-Pub 2024. PMID: 37989028.
19. Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
20. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
21. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
22. Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernández-Boluda JC, Giralt S, Palmer J, Gale RP, DeFilipp Z, Marks DI, van der Poel M, Verdonck LF, Battiwalla M, Diaz MA, Gupta V, Ali H, Litzow MR, Lazarus HM, Gergis U, Bashey A, Liesveld J, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson C, Rizzieri D, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike Bacher V, Wirk B, Jain T, Cutler C, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv 7(15):3993-4002, 2023. e-Pub 2023. PMID: 37134306.
23. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
24. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica 108(7):1900-1908, 2023. e-Pub 2023. PMID: 36779595.
25. Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
26. Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
27. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
28. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
29. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
30. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2023. PMID: 36502492.
31. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther 29(2):71-81, 2023. e-Pub 2023. PMID: 36436780.
32. Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica 108(1):150-160, 2023. e-Pub 2023. PMID: 35443559.
33. Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood 140(24):2533-2548, 2022. e-Pub 2022. PMID: 35969835.
34. Arslan, S, Hsu, JM, Oran, B, Sica, RA, Liu, H, Silverman, M, Bejanyan, N, DiStasi, A, McCallum, R, Quintero, S, Garrett, G, Wang, K, Smith, E, Hoang, T, Shahim, T, Crisostomo, J, Wilga-Savitski, A, Pickering, J, Angelo, LS, Smith, A, Vera, JF, Koneru, M. AML-109 Preliminary Results of MT-401 in Post-Transplant Measurable Residual Disease Positive (MRD+) Acute Myeloid Leukemia (AML) Patients. Clinical Lymphoma, Myeloma and Leukemia 22:S213-S214, 2022. e-Pub 2022. PMID: 35969835.
35. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
36. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
37. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
38. Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernández-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W. Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. Br J Haematol 198(4):785-789, 2022. e-Pub 2022. PMID: 35658101.
39. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
40. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
41. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
42. Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica Online ahead of print(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
43. Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 28(4):187.e1-187.e10, 2022. e-Pub 2022. PMID: 35081472.
44. Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol 8(3):404-411, 2022. e-Pub 2022. PMID: 35024768.
45. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
46. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. e-Pub 2022. PMID: 34876697.
47. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
48. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
49. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2022. PMID: 34135465.
50. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
51. Toruner GA, Thakral B, Tang Z, Tang G, Medeiros LJ, Oran B. Clonal cytogenetic abnormalities in donor-derived cells after sex mismatched allogeneic stem cell transplantation. Cancer Genet 258-259:120-130, 2021. e-Pub 2021. PMID: 34715428.
52. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
53. Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther 27(11):921.e1-921.e10, 2021. e-Pub 2021. PMID: 34403791.
54. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol 39(30):3328-3339, 2021. e-Pub 2021. PMID: 34106753.
55. Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
56. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
57. Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 27(8):642-649, 2021. e-Pub 2021. PMID: 34304802.
58. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
59. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
60. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
61. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
62. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
63. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 4(24):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
64. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
65. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
66. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
67. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
68. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
69. Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther 27(1):6-20, 2021. e-Pub 2021. PMID: 32966881.
70. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106(1):269-274, 2021. e-Pub 2021. PMID: 32107328.
71. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2021. PMID: 32604096.
72. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
73. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
74. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis 22(5):e13395, 2020. e-Pub 2020. PMID: 32602954.
75. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
76. Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Graft Failure After the First Allograft. Am J Hematol, 2020. e-Pub 2024. PMID: 32602112.
77. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
78. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
79. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
80. Popat UR, Saliba RM, Mehta RS, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriae P, Khouri IF, Marin D, Nieto Y, Betul Oran B, Saini N, Srour SA, Rezvani K, Qalzibash M, Molldren JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. BBMT 26(3, Supplement), 2020. e-Pub 2020.
81. Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv 4(4):740-754, 2020. e-Pub 2020. PMID: 32092137.
82. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
83. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
84. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Oran B, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
85. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
86. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
87. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(Supplement_1):47, 2019. e-Pub 2019.
88. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019.
89. Figgins B, Hammerstrom A, Ariza-Heredia E, Oran B, Milton DR, Yeh J. Characterization of Viral Infections after Antithymocyte Globulin-Based Conditioning in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 25(9):1837-1843, 2019. e-Pub 2019. PMID: 31128324.
90. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
91. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
92. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
93. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv 3(12):1826-1836, 2019. e-Pub 2019. PMID: 31201170.
94. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
95. Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
96. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
97. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
98. Mehta RS, Oran B. The Optimal Killer Cell Immunoglobulin-Like Receptor Donor-We Can Recognize, but Can We Search?. Biol Blood Marrow Transplant 25(1):e3-e4, 2019. e-Pub 2019. PMID: 30472435.
99. Oran B, Daver N. Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. Biol Blood Marrow Transplant 25(1):e1-e2, 2019. e-Pub 2019. PMID: 30500441.
100. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
101. de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant 24(10):2017-2024, 2018. e-Pub 2018. PMID: 29933073.
102. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
103. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
104. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
105. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res 24(10):2304-2311, 2018. e-Pub 2018. PMID: 29476021.
106. Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected or Unmodified Hematopoietic Stem Cells Transplants. Biol Blood Marrow Transplant 24(5):1079-1087, 2018. e-Pub 2018. PMID: 29325829.
107. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24(4):526, 2018. e-Pub 2018. PMID: 29634689.
108. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
109. Kongtim P, Parmar S, Milton D, Rondon G, Chen J, Oran B, Popat UR, Hosing CM, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24(3), 2018. e-Pub 2018.
110. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24(3):282-291, 2018. e-Pub 2018. PMID: 29431743.
111. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
112. Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O. Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant. Am J Hematol 93(2):222-231, 2018. e-Pub 2018. PMID: 29090473.
113. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
114. Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem-Cell Transplant Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
115. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
116. Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
117. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
118. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
119. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
120. Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W, International Blood ALWCOTCF, Research MT, Match Registry ACBTNMDPT, theMedicalCollegeofWisconsin. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer 123(11):2035-2042, 2017. e-Pub 2017. PMID: 28117898.
121. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
122. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
123. El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DP. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant 52(3):476-479, 2017. e-Pub 2017. PMID: 27941772.
124. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
125. Yuca SA, Cimbek EA, Sen Y, Guvenc O, Vatansev H, Bugrul F, Gun F, Oran B. The Relationship between Metabolic Parameters, Cardiac Parameters and MIC-1/GDF15 in Obese Children. Exp Clin Endocrinol Diabetes 125(2):86-90, 2017. e-Pub 2017. PMID: 27750354.
126. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
127. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
128. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2017. PMID: 27595282.
129. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
130. Koplay M, Kizilca O, Cimen D, Sivri M, Erdogan H, Guvenc O, Oc M, Oran B. Prospective ECG-gated high-pitch dual-source cardiac CT angiography in the diagnosis of congenital cardiovascular abnormalities: Radiation dose and diagnostic efficacy in a pediatric population. Diagn Interv Imaging 97(11):1141-1150, 2016. e-Pub 2016. PMID: 27156243.
131. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
132. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
133. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1-23, 2016. e-Pub 2016. PMID: 26472485.
134. Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant 22(7):1218-1226, 2016. e-Pub 2016. PMID: 27058617.
135. Artac H, Vatansev H, Cimen D, Arslan D, Kaya F, Kayis SA, Oran B. N-terminal-pro brain natriuretic peptide levels in children with allergic rhinitis. Turk J Med Sci 46(4):1130-4, 2016. e-Pub 2016. PMID: 27513415.
136. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
137. Kaya F, Arslan D, Vatansev H, Kose D, Cimen D, Akyurek F, Oran B, Koksal Y. Growth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancers. J Pediatr Hematol Oncol 38(3):e107-12, 2016. e-Pub 2016. PMID: 26907646.
138. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
139. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
140. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant 22(2):248-257, 2016. e-Pub 2016. PMID: 26327629.
141. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
142. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
143. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
144. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
145. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2015. e-Pub 2015. PMID: 26343946.
146. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-1412, 2015. e-Pub 2015. PMID: 25840338.
147. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
148. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
149. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50(Supplement 2):S55-62, 2015. e-Pub 2015. PMID: 26039209.
150. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase Ii Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
151. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
152. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
153. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients With Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2015. PMID: 25540936.
154. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med 3(12):1435-43, 2014. e-Pub 2014. PMID: 25378655.
155. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
156. Koplay M, Cimen D, Sivri M, Guvenc O, Arslan D, Nayman A, Oran B. Truncus arteriosus: Diagnosis with dual-source computed tomography angiography and low radiation dose. World J Radiol 6(11):886-9, 2014. e-Pub 2014. PMID: 25431644.
157. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
158. Arslan D, Cimen D, Guvenc O, Oran B, Yilmaz FH. Assessment of P-wave dispersion in children with atrial septal aneurysm. Cardiol Young 24(5):918-22, 2014. e-Pub 2014. PMID: 24067159.
159. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
160. Arslan D, Guvenc O, Cimen D, Ulu H, Oran B. Prolonged QT dispersion in the infants of diabetic mothers. Pediatr Cardiol 35(6):1052-6, 2014. e-Pub 2014. PMID: 24740627.
161. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16(8):1153-7, 2014. e-Pub 2014. PMID: 24582458.
162. Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant 49(8):1029-35, 2014. e-Pub 2014. PMID: 24887379.
163. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
164. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28(3):658-65, 2014. e-Pub 2014. PMID: 23989431.
165. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
166. Arslan D, Cimen D, Guvenc O, Sert A, Oktay A, Oran B. A case of Seckel syndrome with tricuspid atresia. Genet Couns 25(2):171-5, 2014. e-Pub 2014. PMID: 25059015.
167. Oran B, Bodur AS, Arslan D, Cimen D, Guvenc O. Normal M mode values in healthy Turkish children. Turk J Med Sci 44(5):756-63, 2014. e-Pub 2014. PMID: 25539541.
168. Arslan D, Oran B, Vatansev H, Cimen D, Guvenc O. The usefulness of plasma asymmetric dimethylarginine (ADMA) levels and tissue doppler echocardiography for heart function in term infants born to mothers with gestational diabetes mellitus. J Matern Fetal Neonatal Med 26(17):1742-8, 2013. e-Pub 2013. PMID: 23614659.
169. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 48(11):1415-20, 2013. e-Pub 2013. PMID: 23933764.
170. Arslan D, Oran B, Yazilitas F, Peru H, Cimen D, Vatansev H. P-wave duration and dispersion in children with uncomplicated familial Mediterranean fever. Mod Rheumatol 23(6):1166-71, 2013. e-Pub 2013. PMID: 23274952.
171. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
172. Arslan D, Cihan T, Kose D, Vatansev H, Cimen D, Koksal Y, Oran B, Akyurek F. Growth-differentiation factor-15 and tissue doppler imaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors. Clin Biochem 46(13-14):1239-43, 2013. e-Pub 2013. PMID: 23850849.
173. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 2013. e-Pub 2013. PMID: 23775587.
174. Oran B, Ozturk K, Cimen D, Vatansev H, Bulut S, Arslan D. Release of NT-pro brain natriuretic peptide in children before and after adenotonsillectomy. Int J Pediatr Otorhinolaryngol 77(5):666-9, 2013. e-Pub 2013. PMID: 23415956.
175. Arslan D, Cimen D, Guvenc O, Kaya F, Sert A, Oran B. Platelet distribution width and mean platelet volume in children with pulmonary arterial hypertension secondary to congenital heart disease with left-to-right shunt: new indices of severity?. Pediatr Cardiol 34(4):1013-6, 2013. e-Pub 2013. PMID: 23254645.
176. Sap F, Karatas Z, Altin H, Alp H, Oran B, Baysal T, Karaarslan S. Dispersion durations of P-wave and QT interval in children with congenital heart disease and pulmonary arterial hypertension. Pediatr Cardiol 34(3):591-6, 2013. e-Pub 2013. PMID: 22972516.
177. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
178. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
179. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
180. Ciftci I, Arslan D, Peru H, Cimen D, Oran B, Gunduz M. Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction?. Med Arch 67(3):202-4, 2013. e-Pub 2013. PMID: 23848044.
181. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
182. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97(12):1916-24, 2012. e-Pub 2012. PMID: 22773600.
183. Alp H, Karaarslan S, Baysal T, Cimen D, Ors R, Oran B. Normal values of left and right ventricular function measured by M-mode, pulsed doppler and Doppler tissue imaging in healthy term neonates during a 1-year period. Early Hum Dev 88(11):853-9, 2012. e-Pub 2012. PMID: 22805997.
184. Koplay M, Erol C, Paksoy Y, Uysal E, Arslan D, Oran B. Hemitruncus arteriosus: cardiac magnetic resonance angiography findings. Congenit Heart Dis 7(5):E66-9, 2012. e-Pub 2012. PMID: 22985459.
185. Tokgoz H, Aydin K, Oran B, Kiyici A. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 28(7):1049-53, 2012. e-Pub 2012. PMID: 22645062.
186. Karaarslan S, Alp H, Baysal T, Cimen D, Ors R, Oran B. Is myocardial performance index useful in differential diagnosis of moderate and severe hypoxic-ischaemic encephalopathy? A serial Doppler echocardiographic evaluation. Cardiol Young 22(3):335-40, 2012. e-Pub 2012. PMID: 22325593.
187. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 47(4):494-8, 2012. e-Pub 2012. PMID: 21602900.
188. Kocaoglu C, Sert A, Aypar E, Oran B, Odabas D, Arslan D, Akin F. P-wave dispersion in children with acute rheumatic fever. Pediatr Cardiol 33(1):90-4, 2012. e-Pub 2012. PMID: 21898108.
189. Alp H, Karaaslan S, Baysal T, Oran B, Ors R. Hipoksik iskemik ensefalopatili yenidoganlarda sol ve sag ventrikul "pulsed" ve doku Doppler miyokart performans indeks degerlerinin Z-skorla karsilastirmasi. Anadolu Kardiyol Derg 11(8):719-25, 2011. e-Pub 2011. PMID: 22088860.
190. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 17(9):1327-34, 2011. e-Pub 2011. PMID: 21232621.
191. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17(7):1025-32, 2011. e-Pub 2011. PMID: 21047561.
192. McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 35(6):757-61, 2011. e-Pub 2011. PMID: 21232793.
193. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 17(3):356-64, 2011. e-Pub 2011. PMID: 20553926.
194. Atabek ME, Cagan HH, Selver Eklioglu B, Oran B. Absence of increase in carotid artery intima-media thickness in infants of diabetic mothers. J Clin Res Pediatr Endocrinol 3(3):144-8, 2011. e-Pub 2011. PMID: 21911328.
195. Cimen O, Oran B, Cimen D, Baysal T, Karaaslan S, Unal E, Basarili K, Buyukbas S. Release of N-terminal pro-brain natriuretic peptide in children with acute rheumatic carditis. Cardiol Young 20(3):297-301, 2010. e-Pub 2010. PMID: 20416140.
196. Baysal T, Koksal Y, Oran B, Sen M, Unal E, Cimen D. Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines. Pediatr Hematol Oncol 27(1):13-23, 2010. e-Pub 2010. PMID: 20121551.
197. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant 45(1):21-4, 2010. e-Pub 2010. PMID: 19421171.
198. Akdemir B, Oran B, Gunes S, Karaaslan S. Prediction of aortic diameter values in healthy Turkish infants, children, and adolescents by using artificial neural network. J Med Syst 33(5):379-88, 2009. e-Pub 2009. PMID: 19827264.
199. Pirgon O, Atabek ME, Oran B, Suleymanoglu S, Meral C. Treatment with human chorionic gonadotropin induces left ventricular mass in cryptorchid boys. J Pediatr Endocrinol Metab 22(5):449-54, 2009. e-Pub 2009. PMID: 19618664.
200. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 2009. e-Pub 2009. PMID: 19011667.
201. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 2009. e-Pub 2009. PMID: 19361753.
202. Baysal T, Peru H, Oran B, Sahin TK, Koksal Y, Karaaslan S. Left ventricular diastolic function evaluated with tissue Doppler imaging in children with familial Mediterranean fever. Clin Rheumatol 28(1):23-8, 2009. e-Pub 2009. PMID: 18716732.
203. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid 16(2):103-7, 2009. e-Pub 2009. PMID: 20536404.
204. Peru H, Altun B, Dogan M, Kara F, Elmaci AM, Oran B. The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 27(6):689-94, 2008. e-Pub 2008. PMID: 17926078.
205. Kurban S, Mehmetoglu I, Oran B, Kiyici A. Homocysteine levels and total antioxidant capacity in children with acute rheumatic fever. Clin Biochem 41(1-2):26-9, 2008. e-Pub 2008. PMID: 17964295.
206. Pirgon O, Atabek ME, Oran B, Guclu R. Atherogenic lipid profile and systolic blood pressure are associated with carotid artery intima-media thickness in children with Turner syndrome. J Clin Res Pediatr Endocrinol 1(2):62-71, 2008. e-Pub 2008. PMID: 21318066.
207. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 2007. e-Pub 2007. PMID: 17611563.
208. Baysal T, Oran B, Dogan M, Cimen D, Elmas S, Karaaslan S. Beta-blocker treatment in an adolescent with amitriptyline intoxication. Anadolu Kardiyol Derg 7(3):324-5, 2007. e-Pub 2007. PMID: 17785228.
209. Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol 22(5):550-4, 2007. e-Pub 2007. PMID: 17690060.
210. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 2007. e-Pub 2007. PMID: 17382253.
211. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
212. Koksal Y, Unal E, Aribas OK, Oran B. An uncommon extrapulmonary sequestration located in the upper posterior mediastinum associated with the azygos lobe in a child. J Thorac Cardiovasc Surg 133(4):1110-1, 2007. e-Pub 2007. PMID: 17382671.
213. Unal E, Oran B, Baysal T, Baspinar O, Keser M, Karaarslan S, Arbag H. Pulmonary arterial pressure in infants with laryngomalacia. Int J Pediatr Otorhinolaryngol 70(12):2067-71, 2006. e-Pub 2006. PMID: 16962179.
214. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108(12):3945-7, 2006. e-Pub 2006. PMID: 16926284.
215. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4):299-303, 2006. e-Pub 2006. PMID: 16819437.
216. Baspinar O, Karaaslan S, Oran B, Baysal T, Elmaci AM, Yorulmaz A. Prevalence and distribution of children with congenital heart diseases in the central Anatolian region, Turkey. Turk J Pediatr 48(3):237-43, 2006. e-Pub 2006. PMID: 17172068.
217. Oran B, Ekici G, Reisli I, Arbag H, Baspinar O, Baysal T, Dogan M, Cimen D, Karaaslan S. Pulmonary arterial pressure in children with croup syndrome. Am J Otolaryngol 27(3):150-3, 2006. e-Pub 2006. PMID: 16647977.
218. Baspinar O, Karaaslan S, Oran B. PISA method for assessment of mitral regurgitation in children. Anadolu Kardiyol Derg 5(3):167-71, 2005. e-Pub 2005. PMID: 16140644.
219. Baysal T, Oran B, Baspinar O, Dogan M, Karaaslan S. Cardiac troponin I elevation in paediatric cardiac catheterization. Anadolu Kardiyol Derg 5(2):112-5, 2005. e-Pub 2005. PMID: 15939685.
220. Baysal T, Oran B, Dogan M, Cimen D, Karaaslan S. The myocardial performance index in children with isolated left-to-right shunt lesions. Anadolu Kardiyol Derg 5(2):108-11, 2005. e-Pub 2005. PMID: 15939684.
221. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 35(6):567-75, 2005. e-Pub 2005. PMID: 15665842.
222. Baspinar O, Karaaslan S, Oran B, Baysal T, Keles S. Congenital aneurysm of the muscular interventricular septum in a child. Turk J Pediatr 47(1):82-4, 2005. e-Pub 2005. PMID: 15884636.
223. Demiroren K, Cam L, Oran B, Koc H, Baspinar O, Baysal T, Karaaslan S. Echocardiographic measurements in infants of diabetic mothers and macrosomic infants of nondiabetic mothers. J Perinat Med 33(3):232-5, 2005. e-Pub 2005. PMID: 15914346.
224. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Ann Oncol 15(11):1622-6, 2004. e-Pub 2004. PMID: 15520062.
225. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92(4):747-51, 2004. e-Pub 2004. PMID: 15467905.
226. Demiroren K, Tastekin G, Oran B. Diagnostic role of 99mTc hexamethyl-propyleneamine oxime brain single photon emission computed tomography in Sydenham's chorea. Pediatr Int 46(4):450-5, 2004. e-Pub 2004. PMID: 15310312.
227. Atabek ME, Pirgon O, Oran B, Erkul I, Kurtoglu S. Increased cardiac troponin I concentration in diabetic ketoacidosis. J Pediatr Endocrinol Metab 17(8):1077-82, 2004. e-Pub 2004. PMID: 15379418.
228. Reisli I, Oran B, Baspinar O, Baysal T, Karaaslan S. Pulmonary arterial pressure in children with allergic rhinitis. Am J Rhinol 18(4):227-32, 2004. e-Pub 2004. PMID: 15490569.
229. Baysal T, Gormus N, Avunduk MC, Oran B, Yeniterzi M, Karaaslan S. Pulmonary right-upper lobar arteriovenous fistula in an infant with progressive cyanosis. Anadolu Kardiyol Derg 4(2):184-6, 2004. e-Pub 2004. PMID: 15165958.
230. Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol 21(1):31-40, 2004. e-Pub 2004. PMID: 15034211.
231. Karaaslan S, Oran B, Caliskan U, Baysal T, Baspinar O, Tas A. Miyokardit Olgusunda Yuksek Doz Immunglobulin Uygulanmasini izleyen Hemoliz. Turk J Haematol 20(4):237-40, 2003. e-Pub 2003. PMID: 27263521.
232. Karaaslan S, Demiroren S, Oran B, Baysal T, Baspinar O, Ucar C. Criteria for judging the improvement in subclinical rheumatic valvitis. Cardiol Young 13(6):500-5, 2003. e-Pub 2003. PMID: 14982289.
233. Baspinar O, Karaaslan S, Oran B, Reisli I, Keles S, Baysal T. Pulmonary vascular sling with aberrant right upper lobe pulmonary artery in a child. Anadolu Kardiyol Derg 3(4):370, 2003. e-Pub 2003. PMID: 14675895.
234. Baspinar O, Ucar C, Baysal T, Oran B, Karaaslan S. Echocardiographic recognition of cardiac leukemic tumors in a child successfully treated with chemotherapy. Anadolu Kardiyol Derg 3(3):286, 2003. e-Pub 2003. PMID: 12967903.
235. Karaaslan S, Baysal T, Baspinar O, Oran B. Adolescent with variant angina. Pediatr Int 45(4):478-80, 2003. e-Pub 2003. PMID: 12911490.
236. Oran B, Cam L, Baspinar O, Baysal T, Reisli I, Peru H, Karaaslan S, Koc H, Gurbilek M. Cardiac troponin-I in the serum of infants of diabetic mothers. Cardiol Young 13(3):248-52, 2003. e-Pub 2003. PMID: 12903871.
237. Atabek ME, Yavuz H, Oran B, Karaaslan S, Erkul I. Plasmapheresis as an adjunct treatment in severe botulism. Intensive Care Med 28(6):814, 2002. e-Pub 2002. PMID: 12269246.
238. Oran B, Coban H, Karaaslan S, Atabek E, Gurbilek M, Erkul I. Serum cardiac troponin-I in active rheumatic carditis. Indian J Pediatr 68(10):943-4, 2001. e-Pub 2001. PMID: 11758130.
239. Oran B, Atabek E, Karaaslan S, Reisli Y, Gultekin F, Erkul Y. Oxygen free radicals in children with acute rheumatic fever. Cardiol Young 11(3):285-8, 2001. e-Pub 2001. PMID: 11388622.
240. Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, Ozcebe O, Dundar S, Kirazli S. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost 7(2):126-30, 2001. e-Pub 2001. PMID: 11292190.
241. Oran B, Tastekin A, Karaaslan S, Bas L, Aycicek A, Ceri A, Sutcu A, Erkul I. Prophylactic efficiency of 3-weekly benzathine penicillin G in rheumatic fever. Indian J Pediatr 67(3):163-7, 2000. e-Pub 2000. PMID: 10838716.
242. Karaaslan S, Oran B, Reisli I, Erkul I. Acute rheumatic fever in Konya, Turkey. Pediatr Int 42(1):71-5, 2000. e-Pub 2000. PMID: 10703240.
243. Cora T, Acar H, Oran B. A partial trisomy 15q due to 15;17 translocation detected by conventional cytogenetic and FISH techniques. Genet Couns 11(1):25-32, 2000. e-Pub 2000. PMID: 10756424.
244. Koc H, Altunhan H, Dilsiz A, Kaymakci A, Duman S, Oran B, Erkul I. Testicular changes in newborn rats exposed to phototherapy. Pediatr Dev Pathol 2(4):333-6, 1999. e-Pub 1999. PMID: 10347276.
245. Akcoral A, Oran B, Tavli V, Oren H, Cevik NT. Transient right sided hypertrophic cardiomyopathy in an infant born to a diabetic mother. Indian J Pediatr 63(5):700-3, 1996. e-Pub 1996. PMID: 10830045.
246. Abasiyanik A, Oran B, Kaymakci A, Yasar C, Caliskan U, Erkul I. Conn syndrome in a child, caused by adrenal adenoma. J Pediatr Surg 31(3):430-2, 1996. e-Pub 1996. PMID: 8708918.
247. Akcoral A, Oran B, Tavli V, Unal N, Cevik NT. Effects of high-dose intravenous methylprednisolone in children with acute rheumatic carditis. Acta Paediatr Jpn 38(1):28-31, 1996. e-Pub 1996. PMID: 8992855.
248. Oran B, Ceri A, Yilmaz H, Kabakus N, Aycicek A, Erkul I. Hydrocephalus in mumps meningoencephalitis: case report. Pediatr Infect Dis J 14(8):724-5, 1995. e-Pub 1995. PMID: 8532441.
249. Kavukcu S, Tavli V, Fadiloglu M, Akhunlar H, Oran B, Akcoral A. Urinary enzyme changes in children undergoing cineangiographic evaluation using iopromid. Int Urol Nephrol 27(2):131-5, 1995. e-Pub 1995. PMID: 7591567.
250. Akcoral A, Ozaksoy D, Oran B, Narin N, Cevik NT. A new and rare form of Williams' syndrome. Acta Paediatr Jpn 35(3):247-51, 1993. e-Pub 1993. PMID: 8351994.
251. Senaati S, Caner H, Oran BM. Resolving cerebral hematoma mimicking cerebral abscess. AJR Am J Roentgenol 159(4):903, 1992. e-Pub 1992. PMID: 1529869.

Invited Articles

1. Oran B. Is there a role for therapy after transplant?. Best Pract Res Clin Haematol, 2015. e-Pub 2024. PMID: 26590769.
2. Oran B. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?. Clin Lymphoma Myeloma Leuk 15 Suppl:S43-9, 2015. e-Pub 2015. PMID: 26297277.
3. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13(Supplement 2):S282-8, 2013. e-Pub 2013. PMID: 24290213.
4. Oran B. Can double-cord transplants provide a more potent graft-vs-leukemia effect?. Best Pract Res Clin Haematol 25(4):479-82, 2012. e-Pub 2012. PMID: 23200545.
5. Oran B, Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012:215-22, 2012. e-Pub 2012. PMID: 23233584.
6. Oran B, Weisdorf DJ. Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 18(6):395-400, 2011. e-Pub 2011. PMID: 21912256.
7. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 18(6):388-94, 2011. e-Pub 2011. PMID: 21897227.

Review Articles

1. Oran I, Oran B. Ischemia-Modified Albumin as a Marker of Acute Coronary Syndrome: The Case for Revising the Concept of "N-Terminal Modification" to "Fatty Acid Occupation" of Albumin. Dis Markers 2017:5692583, 2017. e-Pub 2017. PMID: 28356609.
2. Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJ. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne) 2:89, 2015. e-Pub 2015. PMID: 26697430.
3. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 74(2):131-5, 2003. e-Pub 2003. PMID: 14508801.

Other Articles

1. Oran, B, De Lima, M, Garcia-Manero, G Erratum. Blood Advances 5(6):1755-1756, 2021. PMID: 33755091.
2. Oran B.

Editorials

1. Oran B, Daver N. Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. Biology of Blood and Marrow Transplantation(25):e1-e2, 2019.
2. Mehta RS, Oran B. The Optimal Killer Cell Immunoglobulin-Like Receptor Donor-We Can Recognize, but Can We Search?. Biology of Blood and Marrow Transplantation(25):e3-e4, 2019.
3. Oran B, Shpall EJ. Allele-Level HLA Cord Blood Matching Matters. Blood 123(1):8-9, 2014. PMID: 24385496.

Abstracts

1. Oran B, Toruner GA, Kanagal-Shamanna R, Al-Atrash G, Rondon G, Chen G, Im J, Marin D, Kebriaei P, Popat U, Ramdial JL, Smallbone P, Champlin RE, Shpall EJ. Predictors of Outcomes in Acute Myeloid Leukemia with KMT2A Rearrangements after Allogeneic Stem Cell Transplantation. EHA 2025, 2025. e-Pub 2025.
2. Popat U, Jr RB, Thall P, Alousi A, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Valdez B, Qazilbash M, Champlin R, Shpall E, Andersson B. Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study. ASCO 2025, 2025. e-Pub 2025.
3. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. ASTCT 2025, 2025. e-Pub 2025.
4. Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. ASTCT 2025, 2025. e-Pub 2025.
5. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. ASTCT 2025, 2025. e-Pub 2025.
6. Smallbone P, Cao K, Saliba RM, Alvarez M, Fingrut WB, Aljawai Y, Olson AL, Alousi AM, Chen G, Ramdial J, Champlin RE, Shpall EJ, Oran B. HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide. ASH 2024, 2024. e-Pub 2024.
7. Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. ASH 2024, 2024. e-Pub 2024.
8. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. ASH2024, 2024. e-Pub 2024.
9. Ramdial J, Clemente L, Banerjee P, Dabaja BS, Al-Atrash G, Alousi AM, Oran B, Popat U, Im JS, Srour SA, Chen G, Kebriaei P, Hosing C, Marin D, Rezvani K, Shpall EJ, Champlin RE. Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies. ASH 2024, 2024. e-Pub 2024.
10. Alatrash G, Knape C, Whited L, Sui D, Haymaker CL, Yeh J, Marcotulli M, Sukhumalchandra P, John LS, Lu H, Duenas DE, Wistuba I, Perez JM, Espiridion BS, Bassett RL, Kadia TM, DiNardo CD, Ravandi F, Ramdial J, Mehta RS, Alousi AM, Oran B, Khouri IF, Bashir Q, Hosing C, Qazilbash MH, Im JS, Kebriaei P, Bachireddy P, Molldrem JJ, Jorgensen JL, Wang SA, WANG W, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Daver N. A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. ASH 2024, 2024. e-Pub 2024.
11. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 142(Supplement 1):4988-4990, 2023. e-Pub 2023.
12. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee HC, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood 142(Supplement 1):4972, 2023. e-Pub 2023.
13. Atluri H, DiGennaro J, Patel KP, Routbort M, Oran B, Issa GC, Short NJ, Daver N, Kadia TM, Ravandi F, Popat UR, Champlin RE, Shpall EJ, Pierce S, Kanagal-Shamanna R, Ok CY, Tang G, Wang SA, Luthra R, Lasry A, Nadorp B, Chroni A, Eisfeld A, Aifantis I, Al Ali NH, Sallman DA, Lancet J, Chan O, Padron E, Xie Z, Medeiros L, DiNardo CD, Komrokji RS, Loghavi S. Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia. Blood 142(Supplement 1):959, 2023. e-Pub 2023.
14. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood 142(Supplement 1):4920, 2023. e-Pub 2023.
15. Jain T, Estrada-Merly, Kim S, Queralt Salas M, Andrade Campos M, Elmariah H, Kumar R, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott BL, Gupta V, Saber W. Posttransplant Cyclophosphamide-Based Transplantation from Haploidentical Donors Has Similar Outcomes As Unrelated Donor Transplantation in Myelofibrosis: A Center for International BMT Research (CIBMTR) Study. 2023 TCT Meetings of ASTCT and CIBMTR 29(2), 2023. e-Pub 2023.
16. Popat UR, Saliba RM, Mehta, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis, Hosing, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Hagop Kantarjian H, Andersson BS, Champlin RE, Shpall E. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. 2023 TCT Meetings of ASTCT and CIBMTR 29(2), 2023. e-Pub 2023.
17. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir B, Hosing CM, Hulbis AM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. 2023 TCT Meetings of ASTCT and CIBMTR 29(2), 2023. e-Pub 2023.
18. Popat UR, Lontos K, Bassett RL, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Oran B, Olson AL, Qazilbash MH, Ramdial JL, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules. Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
19. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash Q, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, and Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 2022 ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
20. Champlin RE, Bachar Lustig E, Bashir Q, Oran B, Kornblau SM, Hosing, Alousi AM, Popat UR, McCarty JM, Thall PF, Dabaja BS, Liu W, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, Fang P, Kaur I, Rezvani K, Shpall EJ, Reisner Y. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Blood 2022 ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
21. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
22. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi AM, Olson AL, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin RE, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
23. Oran B, Champlin RE, Thall PF, McCarty JM, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT). Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
24. Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
25. Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short N, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Bivins CA, Mehta RS, Alatrash G, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
26. Ramdial JL, Clemente-Sevilla L, Soebbing D, Dabaja BS, Thall PF, Alatrash G, Alousi AM, Mehta RS, Popat UR, Kebriaei P, Oran B, Rezvani K, Shpall EJ, Champlin RE. A Phase II Clinical Trial of "Off-the-Shelf" NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies. Blood 2022 ASH Annual Meetings 140(Supplement 1), 2022. e-Pub 2022.
27. Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, MD, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. Blood 2022 ASH Annual Meeting 140(Supplement 1), 2022. e-Pub 2022.
28. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022. e-Pub 2022.
29. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
30. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
31. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
32. Ong F, Ravandi F, Popat UR, Kadia TM, Daver NG, Dinardo CD, Konopleva M, Borthakur G, Shpall EJ, Oran B, Alatrash G, Mehta RS, Jabbour E, Yilmaz M, Issa GC, Garcia-Manero G, Maiti A, Abbas H, Champlin RE, Short J. Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 2022 ASCO Annual Meeting 40(16_suppl):abstr 7038, 2022. e-Pub 2022.
33. Feurstein SK, Trottier AM, Estrada-Merly N, Pozsga M, McNeely K, Drazer MW, Scott BL, Oran B, Lindsley C, Nakamura R, Sobecks RM, Kim S, Spellman SR, Saber W, Godley LA. Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation. Blood 2021 ASH Annual Meeting 138(Supplement 1):320, 2021. e-Pub 2021.
34. Murthy GSG, Kim S, Estrada-Merly N, Sobecks RM, Oran B, Nakamura R, Scott BL, Saber W. Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR. Blood 2021 ASH Annual Meeting 138(Supplement 1):912, 2021. e-Pub 2021.
35. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran, B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):1803, 2021. e-Pub 2021.
36. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):1802, 2021. e-Pub 2021.
37. Mei, M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood 2021 ASH Annual Meeting 138(Supplement 1):417, 2021. e-Pub 2021.
38. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):2879, 2021. e-Pub 2021.
39. Popat UR, Bassett R, Thall PF, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravzndi D, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 2021 ASH Annual Meeting 138(Supplement 1):556, 2021. e-Pub 2021.
40. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Al-Atrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Farzaneh M, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2021 ASH Annual Meeting 138(Supplement 1):1779, 2021. e-Pub 2021.
41. Nakamura R, Saber W, Martens MJ, Ramirez, Scott B, B <, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, and Cutler C. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Journal of Clinical Oncology 39(30), 2021. e-Pub 2021.
42. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, |Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, and Cutler C. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Journal of Clinical Oncology, 2021. e-Pub 2021.
43. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazibash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk 2021 SOHO Meeting 21(Supplement 1):S446-S447, 2021. e-Pub 2021.
44. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazibash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. Poster: CT-046: Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk 2021 SOHO Meeting 21(Supplement 1):S258, 2021. e-Pub 2021.
45. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of Clinical Oncology 39(24), 2021. e-Pub 2021.
46. Nakamura R, Saber W, Martens M, Ramirez A, Scott BL, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk JP, Westervelt P, Vasu S, Patnaik MM, Kamble RT, Forman SJ, Sekeres MA, Appelbaum FR, Mendizabal A, Logan B, Horowitz MM, Cutler C. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S2-S3, 2021. e-Pub 2021.
47. Afrough A, Alsfeld LC, Delgado R, Popat U, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Manasanch E, Lee HC, Kaufman G, Patel KK, Orlowski RZ, Pinnix C, Dabaja B, Thomas S, Weber D, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S411-S412, 2021. e-Pub 2021.
48. Andersson BS, Thall P, Valdez BC, Ma J, Chen J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei P, Kornblau SM, Myers A, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 2020 ASH Annual Meeting 136(Supplement 1):37-38, 2020. e-Pub 2020.
49. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Alatrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood 2020 ASH Annual Meeting 136(Supplement 1):10-11, 2020. e-Pub 2020.
50. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott BL, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk JP, Westervelt P, Vasu S, Patnaik MM, Kamble R, Forman SJ, Sekeres MA, Appelbaum FR, Mendizabal AM, Logan B, Horowitz MM, Cutler C. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Blood 2020 ASH Annual Meeting 136(Supplement 1):19-21, 2020. e-Pub 2020.
51. Oran B, Alatrash G, Alousi AM, Mehta RS, Hosing C, Popat UR, Im JS, McCarty JM, Ramos JD, Keer HN, Thall PF, Champlin RE. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood 2020 ASH Annual Meeting 136(Supplement 1):29-30, 2020. e-Pub 2020.
52. Murthy HS, Ahn KW, Estrada-Merly N, Gowda L, Dholaria B, Bal S, Alkhateeb HB, Jagadeesh D, Oran B, Nakamura R, Scott BL, Sauter CS, Foss FM, Kharfan-Dabaja MA, Saber W. Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. Blood 2020 ASH Annual Meeting 136(Supplement 1):28-29, 2020. e-Pub 2020.
53. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea SO, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. Blood 2020 ASH Annual Meeting 136(Supplement 1):39–40, 2020. e-Pub 2020.
54. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma C, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 2020 ASH Annual Meeting 136(Supplement 1):13-14, 2020. e-Pub 2020.
55. Murthy GSG, Kim S, Hu ZH, Estrada-Merly N, Nakamura R, Oran B, Scott BL, Sobecks R, Saber W. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood 2020 ASH Annual Meeting 136(Supplement 1):43-44, 2020. e-Pub 2020.
56. Oran B, Alousi AM, Mehta RS, Marin D, Kebriaei P, Popat UR, Olson AL, McCarty JM, Ramos JD, Bassett R, Keer HN, Thall PF, Champlin RE. Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. Blood 2020 ASH Annual Meeting 136(Supplement 1):10-11, 2020. e-Pub 2020.
57. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 2020 ASH Annual Meeting 136(Supplement 1):22, 2020. e-Pub 2020.
58. Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Alatrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood 2020 ASH Annual Meeting 136(Supplement 1):20-21, 2020. e-Pub 2020.
59. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver N, Champlin RE, Diab A, Alatrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood 2020 ASH Annual Meeting 136(Supplement 1):1, 2020. e-Pub 2020.
60. Joseph J, Milton D, Al-Atrash G, Alousi A, Bashir Q, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Bose P, Pemmaraju N, Verstovsek S, Andersson B, Champlin R, Popat U. MPN-188: Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S333, 2020. e-Pub 2020.
61. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus S, Knape C, Whited L, Gulbis A, Cornelison-Marcotulli M, Rondon G, Popat U, Mehta R, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi A, Daver N, Champlin R, Diab A, Al-Atrash G. Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S201-S202, 2020. e-Pub 2020.
62. Yalniz F, Saliba R, Greenbaum U, Ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei P. AML-317: Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2020 SOHO Annual Meeting 20(Supplement 1):S202, 2020. e-Pub 2020.
63. Joseph J, Milton DR, Chen J, Alatrash G, Alousi AM, Bashir Q, Ciurea SO, Daher M, Im JS, Mehta RS, Oran B, Olson AL, Saini N, Srour SA, Andersson B, Champlin RE, Popat UR. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. J Clin Oncol 2020 ASCO Virtual Scientific Program 38(15_suppl):e1952, 2020. e-Pub 2020.
64. Bashir Q, Thall P, Milton DR, Kawedia JD, Kebriaei P, Patel K, Andersson BS, Nieto Y, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing CM, Popat UR, Oran B, Ciurea SO, Lin P, Weber, Thomas S, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Williams L, Champlin RE, Qazilbash MH. Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S241-S242, 2020. e-Pub 2020.
65. Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S125, 2020. e-Pub 2020.
66. Popat UR, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Biol Blood Marrow Transplant 2020 TCT Meetings 26(3, Supplement):S6-S7, 2020. e-Pub 2020.
67. Mukherjee A, Milton DR, Gulbis A, Ledesma C, Jabbour E, Alousi AM, Bashir Q, Daher M, Oran B, Olson AL, Marin D, Srour S, Kebriaei P, Mehta R, Nemeth K, Popat UR, Im J, Champlin RE, Khouri I. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. Blood 2019 ASH Annual Meeting 134(Supplement_1):4530, 2019. e-Pub 2019.
68. Short NJ, Rafei H, Daver NG, Hwang H, Ning J, Cortes JE, Jorgensen JL, Kadia TM, DiNardo CF, Wang SA, Jabbour E, Popat UR, Oran B, Konopleva MY, Garcia-Manero G, Borthakur GM, Bhalla KN, Issa GC, Kantarjian HM, Ravandi F. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Blood 2019 ASH Annual Meeting 134(Supplement_1):735, 2019. e-Pub 2019.
69. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat UR, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 2019 ASH Annual Meeting 134(Supplement_1):47, 2019. e-Pub 2019.
70. Koller P, Saliba RM, Ledesma C, Rondon G, Popat UR, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, Ciurea SO, Shpall EJ, Jorgensen JL, Wang SA, Jain N, Jabbour E, Kantarjian HM, Champlin RE, Konopleva MY, Kebriaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood 2019 ASH Annual Meeting 134(Supplement_1):4598, 2019. e-Pub 2019.
71. Olson AL, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Li L, Abueg G, Timmons M, Chemaly R, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriae P, Jones RB, Andersson BS, Oran B, Abuddayeh A, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 2019 ASH Annual Meeting 134(Supplement_1):3296, 2019. e-Pub 2019.
72. Champlin RE, Popat UR, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Al-Atrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta RS, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 2019 ASH Annual Meeting 134(Supplement_1):257, 2019. e-Pub 2019.
73. Popat UR, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Partow P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 2019 ASH Annual Meeting 134(Supplement_1):256, 2019. e-Pub 2019.
74. Khouri IF, Milton DR, Ledesma C, Nastoupil L, Jabbour E, Pi A, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat UR, Qazilbash M, Srour S, Samaniego F, Rondon G, Medeiros LJ, Gulbis A, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). Blood 2019 ASH Annual Meeting 134(Supplement_1):322, 2019. e-Pub 2019.
75. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat UR, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 2019 ASH Annual Meeting 134(Supplement_1):42, 2019. e-Pub 2019.
76. Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat UR, Ciurea SO, Kebriaei P, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 2019 ASH Annual Meeting 134(Supplement_1):512, 2019. e-Pub 2019.
77. Oran B, Ahn KW, Fretham C, Shah MV, Nakamura R, Scott BL, Sobecks R, Popat UR, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Blood 2019 ASH Annual Meeting 134(Supplement_1):253, 2019. e-Pub 2019.
78. Olson AL, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Li L, Abueg G, Timmons M, Chemaly R, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones RB, Andersson BS, Oran B, Abuddayeh A, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood 2019 ASH Annual Meeting 134(Supplement_1):3596, 2019. e-Pub 2019.
79. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7007, 2019. e-Pub 2019.
80. Mukherjee M, Milton DR, Jabbour E, Konopleva M, Dinardo CD, Gulbis A, Ravandi F, Daver NG, Kadia TM, Oran B, Popat UR, Ciurea SO, Im JS, Kebriaei P, Mehta RS, Kantarjian HM, Champlin RE, Khouri IF. Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7047, 2019. e-Pub 2019.
81. Rashidi A, Hamadani M, Wang HL, Bolanos J, Lee JW, Ciurea SO, Holland HK, Koc Y, Maertens JA, Stockerl-Goldstein K, Bashey A, Aljurf M, Cutler C, Nakamura R, Oran B, Shaffer BC, Hahn TE, de Lima M, Sandmaier BM, Litzow MR, Weisdorf DJ, Zhang MJ, Romee R, Saber W. HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). Biol Blood Marrow Transplant 2019 TCT Meetings 25(3, Supplement):S59-S60, 2019. e-Pub 2019.
82. Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant. Biol Blood Marrow Transplant 2019 TCT Meetings 25(3, Supplement):S144-S145, 2019. e-Pub 2019.
83. Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Rondon G, Shpall EJ, Varma A, Andersson BS, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. Biol Blood Marrow Transplant 2019 TCT Meetings 25(3, Supplement):S235-S236, 2019. e-Pub 2019.
84. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 2019 TCT Meetings 25(3, Supplement):S116-S117, 2019. e-Pub 2019.
85. Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis. Biol Blood Marrow Transplant 2019 TCT Meetings 25(3, Supplement):S147-S148, 2019. e-Pub 2019.
86. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Alousi AM, Hosing C, Kebriaei P, Popat UR, Giralt S, Ahmed S, Shpall EJ, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Woodworth G, Champlin RE. Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood 2018 ASH Annual Meeting 132(Supplement 1):971, 2018. e-Pub 2018.
87. Lin, P, Westfall Vetri L, Rezvani K, Oran B, Ahmed S, Al-Atrash G, Mehta RS, Rondon G, Kebriaei P, Popat UR, Nieto Y, Hosing C, Jones RB, Qazilbsh MH, Khuri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Blood 2018 ASH Annual Meeting 132(Supplement 1):4667, 2018. e-Pub 2018.
88. Popat, UR, Mehta RS, Bassett RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 2018 ASH Annual Meeting 132(Supplement 1):3373, 2018. e-Pub 2018.
89. Ciurea SO, Borges Bittencourt MC, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Ramos Perez J, Elshazly, Aljadayeh M, Alvarez A, Im JS, PhD, Gheath Al-Atrash O, Mehta RS, Popat UR, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. Blood 2018 ASH Annual Meeting 132(Supplement 1):3450, 2018. e-Pub 2018.
90. Khouri, IF, Milton DR, Ledesma C, Jabbour EJ, Al-Atrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Moldrem JJ, Olson AL, Oran B, Ur P, Qazilash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 2018 ASH Annual Meeting 132(Supplement 1):4584, 2018. e-Pub 2018.
91. Oran B, Ciurea SO, Marin D, McCarty JM, Bashir Q, Ahmed S, Olson AL, Popat UR, Nieto Y, Kebriaei P, Shpall EJ, Agrawal T, and Champlin RE. Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. Blood 2018 ASH Annual Meeting 132(Supplement 1):3426, 2018. e-Pub 2018.
92. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, MD, Popat UR, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 2018 ASH Annual Meeting 132(Supplement 1):483, 2018. e-Pub 2018.
93. Kongtim P, Parmar S, Milton DR, Ramos-Perez J, Rondon G, Chen, J, Chilkulwar AR, Al-Atrash G, Alousi AM, Anderssson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat UR, Chmplin RE, Ciurea SO. Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes. Blood 2018 ASH Annual Meeting 132(Supplement 1):2141, 2018. e-Pub 2018.
94. Saini N, Saliba RM, Rondon G, Maadani F, Ur P, Oran B, Hosing, Bashir Q, Olson AL, ieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 2018 ASH Annual Meeting 132(Supplement 1):3356, 2018. e-Pub 2018.
95. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Al-Atrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Medeiros, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. Blood 2018 ASH Annual Meeting 132(Supplement 1):4651, 2018. e-Pub 2018.
96. Daher M, Cao K, Basar R, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Wang Q, Li L, Saliba RM, Pingali SRK, Popat UR, Hosing C, Olson AL, Oran B, Mehta RS, Champlin RE, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. Blood 2018 ASH Annual Meeting 132(Supplement 1):2077, 2018. e-Pub 2018.
97. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Yesid Alvarado Y, Kadia TM, Kantarjian HM, Patel KP, DiNardo C. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood 2018 ASH Annual Meeting 132(Supplement 1):2667, 2018. e-Pub 2018.
98. Abudayyeh A, Abdelrahim M, Lin HY, Page VD, Rondon G, Andersson B, Martinez C, Tarrand J, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly R, Olson AL, Jones RB, Popat UR, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for symptomatic BKV infection. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):7057, 2018. e-Pub 2018.
99. Kongtim P, Parmar S, Milton D, Rondon G, Chen J, Oran B, Popat UR, Hosing CM, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018 BMT Meetings 24(3, Supplement):S107, 2018. e-Pub 2018.
100. Bashir Q, Milton D, Popat UR, Oran B, Nieto Y, Kebriaei P, Ciurea SO, Ahmed S, Mehta RS, Olson A, Parmar S, Alatrash G, Hosing CM, Shah N, Patel K, Weber D, Thomas S, Manasanch E, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2018 BMT Meetings 24(3, Supplement):S254, 2018. e-Pub 2018.
101. Srour SA, Desai P, Ciurea SO, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Immunosuppression Withdrawal is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant 2018 BMT Meetings 24(3, Supplement):S196-S197, 2018. e-Pub 2018.
102. Shah MV, Saliba RM, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Ahmed S, Alousi AM, Mehta RS, Pemmaraju N, Verstovsek S, Popat UR. Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN). Biol Blood Marrow Transplant 2018 BMT Meetings 24(3, Supplement):S322-S323, 2018. e-Pub 2018.
103. Kongtim, P, Parmar S, Milton DR, Rondon G, Chen J, Oran B, Popat UR, Hosing C, Bashir Q, Kebriaei P, Khour IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Blood 2017 ASH Annual Meeting 130(Supplement 1):4511, 2017. e-Pub 2017.
104. de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Hubbell B, Skikne BS, Craddock C. Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). Blood 2017 ASH Annual Meeting 130(Supplement 1):4512, 2017. e-Pub 2017.
105. Khouri, IF, Gulbis A, Milton DR, Korbling M, Ledesma C, Ahmed S, Alousi AM, Oran B, Anderlini P, Ciurea SO, Bassett RL, Jabbour EJ. Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies. Blood 2017 ASH Annual Meeting 130(Supplement 1):3240, 2017. e-Pub 2017.
106. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 2017 ASH Annual Meeting 130(Supplement 1):3267, 2017. e-Pub 2017.
107. Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin D, Wang SA, Ahmed S, Alous AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat UR, Rondon G, Kebriaei P, Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 2017 ASH Annual Meeting 130(Supplement 1):2031, 2017. e-Pub 2017.
108. Srour SA, Desai P, Ciurea SO, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 2017 ASH Annual Meeting 130(Supplement 1):2007, 2017. e-Pub 2017.
109. Ciurea SO, Soebbing D, Rondon G, Cao K, Alatrash G, Ahmed S, Popat U, Oran B, Bashir Q, Kebriaei P, Karur I, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood 2017 ASH Annual Meeting 130(Supplement 1):3179, 2017. e-Pub 2017.
110. Khouri IF, Jabbour EJ, Ledesma C, Korbling M, Alousi AM, Anderlini P, Oran B, Ciurea SO, Fayad LE, Bassett Jr RL, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results. Blood 2017 ASH Annual Meeting 130(Supplement 1):2036, 2017. e-Pub 2017.
111. Gowda L, Alijadayeh M, Costa M, Ledesma C, Rondon G, Popat U, Alousi AM, Oran B, Shah MV, Ahmed S, Kanagal-Shamanna R, Ciurea SO, Shpall EJ, Luthra R, Hosing C, Qazilbash MH, Rezvani K, Jabbour EJ, Patel KP, Ravandi F, Kantarjian HM, Champlin RE, Kebriaei P. Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT. Blood 2017 ASH Annual Meeting 130(Supplement 1):1992, 2017. e-Pub 2017.
112. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, Kadia T, Konopleva M, DiNardo C, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. Blood 2017 ASH Annual Meeting 130(Supplement 1):3209, 2017. e-Pub 2017.
113. Oran B Garcia-Manero G, Saliba RM, Al-Atrash G, Jabbour E, Popat U, Ravandi F, Alousi A, Kadia T, Konopleva M, Dinardo C, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade. Clin Lymphoma Myeloma Leuk 2017 XXVIII International Association for Comparative Research on Leukemia & Related Diseases Symposium Meeting 17(10_Supplement):S11, 2017. e-Pub 2017.
114. Saliba RM, Song HW, Maher OM, Overman BJ, Hofferek CJ, Pham AV, Chen J, Shpall E, Khouri IF, Champlin RE, Oran B, Ahmed S, Alousi AM, Tran DQ. Higher Frequency of Switched Memory B Cells Predicts the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. Haematologica 22nd Congress of EHA 102(1):163, 2017. e-Pub 2017.
115. Ahmed S, Saliba R, Rondon G, Alousi A, Bashir Q, Ciurea S, Al-Atrash G, Patel K, Olson A, Marin D, Rezvani K, Kebriaei P, Popat U, Shpall E, Champlin R, Oran B. Sorafenib Maintenance in FLT3-ITD Mutated Acute Myeloid Leukemia after Allogeneic Stem Cell Transplant. Haematologica 22nd Congress of EHA 102(s1):323, 2017. e-Pub 2017.
116. Ciurea S, Saliba R, Shah M, Gaballa S, Rondon G, Chen J, Gulbis A, Wallis W, Oran B, Alousi A, Bashir Q, Ahmed S, Marin D, Rezvani K, Shpall E, Qazilbash M, Popat U, Khouri I, c H, Kebriaei P, Daver N, Konopleva M, Pemmaraju N, Ravandi F, Cortes J, Kantarjian H, Champlin R. Haploidentical Transplantation is Safe and Effective for Older Patients with AML/MDS. Haematologica 22nd Congress of EHA 102(s1):375, 2017. e-Pub 2017.
117. Kebriaei P, Saliba R, Wallis W, Garris R, Ledesma C, Rondon G, Popat U, Alousi A, Ahmed S, Oran B, Shpall E, Ciurea S, Ravandi F, Rezvani K, Marin D, Champlin R, Kantarjian H, Jabbour E. Predictive Factors for Developing Veno-Occlusive Disease in Patients With Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin Followed by Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica 22nd Congress of EHA 102(s1):299, 2017. e-Pub 2017.
118. Popat UR, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):7046, 2017. e-Pub 2017.
119. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing CM, Kebriaei P, Oran B, Nieto Y, Olson A, Ciurea SO, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Biol Blood Marrow Transplant 2017 BMT Meetings 23(3, Supplement):S371, 2017. e-Pub 2017.
120. Shah MV, Saliba RM, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. Biol Blood Marrow Transplant 2017 BMT Meetings 23(3, Supplement):S40-S41, 2017. e-Pub 2017.
121. Bashir Q, El Shazly M, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazibash MH. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood 2016 ASH Annual Meeting 128(22):3453, 2016. e-Pub 2016.
122. Kongtim P, Adekola KUA, Milton DR, Ramlal R, Jimenez AM, Chen J, Rondon G, Ahmed S, Oran B, Popat UR, Cortes J, Champlin RE, Ciurea SO. Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. Blood 2016 ASH Annual Meeting 128(22):4583, 2016. e-Pub 2016.
123. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2016 ASH Annual Meeting 128(22):2276, 2016. e-Pub 2016.
124. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood 2016 ASH Annual Meeting 128(22):4680, 2016. e-Pub 2016.
125. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 2016 ASH Annual Meeting 128(22):4676, 2016. e-Pub 2016.
126. Olson AL, Muftuoglu M, Kaur I, Li L, Abueg G, Chemaly R, Yvon E, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones R, Andersson BS, Shah N, Oran B, Abudayyeh A, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. Blood 2016 ASH Annual Meeting 128(22):504, 2016. e-Pub 2016.
127. Veltri LW, Milton DR, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood 2016 ASH Annual Meeting 128(22):4626, 2016. e-Pub 2016.
128. Chen CE, Mao AY, Murray JG, Oran B, Qazilbash MH, Shah N, Ahmed S, Bashir Q, Hosing C, Shpall EJ, Steele JR, Champlin RE, Parmar S. Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. Blood 2016 ASH Annual Meeting 128(22):3554, 2016. e-Pub 2016.
129. Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Shah N, Hosing C, Olson AL, Parmar S, Jones R, Popat UR, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. Blood 2016 ASH Annual Meeting 128(22):4547, 2016. e-Pub 2016.
130. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, Nieto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood 2016 ASH Annual Meeting 128(22):64, 2016. e-Pub 2016.
131. Ciurea SO, Lee DA, Denman C, Schafer J, Bassett Jr RL, Cao K, Rondon G, Chen J, Soebbing D, Willis DB, Ahmed S, Bashir Q, Kebriaei P, Khouri IF, Oran B, Parmar S, POpat UR, Hosing C, Yvon E, Rezvani K, Shpall EJ, Champlin RE. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood 2016 ASH Annual Meeting 128(22):500, 2016. e-Pub 2016.
132. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Blood 2016 ASH Annual Meeting 128(22):3424, 2016. e-Pub 2016.
133. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat UR, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. Blood 2016 ASH Annual Meeting 128(22):5847, 2016. e-Pub 2016.
134. Khouri IF, Wang X, Turturro F, Jabbour E, Carballo-Zarate AA, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Patel KK, Marin D, Nastoupil LJ, Fanale MA, Samuels BI, Gulbis AM, Medeiros LJ, Khoury J. Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL). J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):7551, 2016. e-Pub 2016.
135. Ueda M, MD, Lazarus HM, MD, Cooper B, MD, Caimi P, MD, Creger R, PharmD, Little JA, MD, Baer L, CNP, Brister L, CNP, AOCNP, Malek E, MD, Leland Metheny III, MD, Tomlinson B, MD, Gerson SL, MD, Betul Oran B, MD, Lima MD, MD. Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell Transplant (HCT). Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement), 2016. e-Pub 2016.
136. Ramlal R, Sasaki K, Cerrada SL, Srour SA, Chen J, Rondon G, Rezvani K, Oran B, Olson A, Shpall EJ, Champlin RE, Ciurea SO. Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S375-S376, 2016. e-Pub 2016.
137. de Lima M, Oran B, Papadopoulos EB, Scott BL, William BM, Giralt SA, Champlin RE, Hetzer J, Tosolini A, Laille E, Skikne BS, Craddock C. CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S312-S313, 2016. e-Pub 2016.
138. Popat UR, Lyons G, Bassett R, Chen J, Valdez BC, Kawedia JD, Ahmed S, Alousi AM, Anderlini P, Bashier Q, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Patel K, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S33-S34, 2016. e-Pub 2016.
139. Im JS, Saliba RM, Abraham SC, Ross W, Rondon G, Rashid A, Shpall EJ, Popat UR, Qazilbash M, Hosing CM, Oran B, Shah N, Champlin RE, Alousi AM. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. Blood 2015 ASH Annual Meeting 126(23):1933, 2015. e-Pub 2015.
140. Khouri IF, Saliba RM, Ledesma C, Jabbour EJ, Turturro F, Alatrash G, Ahmed S, Oran B, Patel KK, Olson A, Marin D, Popat UR, Suki TS, Jorgensen JL, Medeiros J, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood 2015 ASH Annual Meeting 126(23):2011, 2015. e-Pub 2015.
141. Oran B, Jorgensen JL, Wang SA, Marin D, Popat UR, Chen J, Ciurea SO, Ahmed S, Bashir Q, Rezvani K, Shpall EJ, Kebriaei P, Champlin RE. Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT. Blood 2015 ASH Annual Meeting 126(23):4342, 2015. e-Pub 2015.
142. Im JS, Saliba RM, Abraham SC, Rashid A, Ross W, Nieto Y, Shpall EJ, Oran B, Olson A, Ahmed S, Popat UR, Rondon G, Qazilbash MH, Shah N, Champlin RE, Alousi AM. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. Blood 2015 ASH Annual Meeting 126(23):3128, 2015. e-Pub 2015.
143. Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2015 ASH Annual Meeting 126(23):4321, 2015. e-Pub 2015.
144. Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget MA, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi A, Oran B, Shah N, Hosing CM, Marin D, Rezvani K, Shpall EJ, Champlin RE. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. Blood 2015 ASH Annual Meeting 126(23):862, 2015. e-Pub 2015.
145. Gabella S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash MH, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood 2015 ASH Annual Meeting 126(23):152, 2015. e-Pub 2015.
146. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi AM, Hosing C, Popat UR, Kebriaei P, Champlin RE, McNiece IK, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. Blood 2015 ASH Annual Meeting 126(23):1190, 2015. e-Pub 2015.
147. Oran B, Saliba RM, Carmazzi Y, Shpall EJ, Rezvani K, De Lima M, Fernandez-Vina M, Champlin RE, Cao K. Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index. Blood 2015 ASH Annual Meeting 126(23):2005, 2015. e-Pub 2015.
148. Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 2015 ASH Annual Meeting 126(23):4376, 2015. e-Pub 2015.
149. Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi AM, Kebriaei P, Qazilbash M, Hosing C, Popat UR, Shpall EJ, Champlin RE, Ciurea SO. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood 2015 ASH Annual Meeting 126(23):3225, 2015. e-Pub 2015.
150. Khouri IF, Sui D, Turturro F, Erwin WD, Bassett Jr RL, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Oran B, Olson A, Popat UR, Patel KK, Qazilbash MH, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros J, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood 2015 ASH Annual Meeting 126(23):3192, 2015. e-Pub 2015.
151. Desai P, Chen J, Liu D, wu J, Ahmed S, Oran B, Ciurea SO, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Patient Choice and Lack of Medicare Coverage for HCT Are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant. Blood 2015 ASH Annual Meeting 126(23):3324, 2015. e-Pub 2015.
152. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. Blood 2015 ASH Annual Meeting 126(23):3136, 2015. e-Pub 2015.
153. Popat UR, Ray G, Bassett Jr RL, Poon MYC, Valdez BC, Konopleva S, Ahmed S, Alousi AM, Andersson B, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Kim S, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin RE. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. Blood 2015 ASH Annual Meeting 126(23):738, 2015. e-Pub 2015.
154. Kongtim P, Popat UR, Jimenez AM, Gabella S, El Fakih RO, Rondon G, Chen J, Bueso-Ramos CE, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian HM, Alousi AM, Hosing CM, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood 2015 ASH Annual Meeting 126(23):4347, 2015. e-Pub 2015.
155. Baljevic M, Cao K, Champlin RE, Hosing C, Shah N, Parmar S, Rezvani K, Olson AL, Shpall EJ, Oran B. Use of dual donor T-cell chimerism to predict prognosis after double cord blood allogeneic transplantation. J Clin Oncol 2015 ASCO Annual Meeting I 33(15_suppl):7093, 2015. e-Pub 2015.
156. Popat UR, Bassett RL, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima MJG, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):7008, 2015. e-Pub 2015.
157. Popat UR, Saliba R, Oran B, Chen J, Alousi AM, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Nieto YL Olson A, Parmar S, Shah N, Shpall EJ, Muzaffar MH, Andersson BS, Champlin RE. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S304, 2015. e-Pub 2015.
158. Thompson PA, Perera T, Marin D, Oran B, Popat UR, Qazilbash MH, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi AM, Ciurea SO, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie DS, Hosing C. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S48, 2015. e-Pub 2015.
159. Hosing C, Munsell M, Armitage S, Sadeghi T, Rezvani K, Oran B, Marin D, Dworsky S, Popat UR, Wilson J, Alousi AM, Shah N, Olson A, JOnes RB, Kebriaei P, Qazilbash MH, Parmar S, McNiece I, Champlin RE, Shpall EJ. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S154-S155, 2015. e-Pub 2015.
160. Baljevic M, Cao K, Champlin RE, Popat UR, Hosing C, Shah N, Parmar S, Rezvani K, Olson A, Shpall EJ, Oran B. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S157, 2015. e-Pub 2015.
161. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreef M, Ravandi F, Cortes J, Champlin RE, Ciurea SO. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S81-S82, 2015. e-Pub 2015.
162. Oran B, Cao K, Saliba RM, Hosing CM, Popat UR, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin RE, Rezvani K, Shpall EJ. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 2014 ASH Annual Meeting 124(21):2531, 2014. e-Pub 2014.
163. Oran B, Champlin RE, Cortes JE, de Lima M, Wang X, Chen HC, Ravandi F, Ciurea SO, Kantarjian HM, Borthakur G. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation. Blood 2014 ASH Annual Meeting 124(21):2531, 2014. e-Pub 2014.
164. Khouri IF, Saliba RM, Xu-Monette ZY, Korbling M, Rondon G, Valverde R, Alousi AM, Anderlini P, Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat UR, Westin JR, Turturro F, Medeiros J, Gulbis AM, Young KH. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood 2014 ASH Annual Meeting 124(21):2563, 2014. e-Pub 2014.
165. Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian H, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 2014 ASH Annual Meeting 124(21):4666, 2014. e-Pub 2014.
166. Tamari R, Oran B, Hilden P, Papadopoulos EB, Kongtim P, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Young JW, Popat UR, Chen J, de Lima M, O'Reilly RJ, Giralt S, Champlin RE, Castro-Malaspina H. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC. Blood 2014 ASH Annual Meeting 124(21):2546, 2014. e-Pub 2014.
167. Popat UR, Fox PS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. Blood 2014 ASH Annual Meeting 124(21):3859, 2014. e-Pub 2014.
168. Sandmaier B, Khaled SK Oran B, Gammon G, Trone D, Frankfurt O. Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. Blood 2014 ASH Annual Meeting 124(21):428, 2014. e-Pub 2014.
169. Gaballa S, Kongtim P, Rondon G, Chen J, Popat U, Ahmed S, Hosing CM, Oran B, Kebriaei P, Parmar S, Shah N, Khouri IF, Champlin RE, Ciurea SO. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood 2014 ASH Annual Meeting 124(21):1245, 2014. e-Pub 2014.
170. Oran B, Saliba RM, Andersson BS, de Lima M, Popat UR, Khouri IF, Kebriaei P, Bashir Q, Ahmed S, Shpall EJ, Champlin RE, Rondon G. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood 2014 ASH Annual Meeting 124(21):2533, 2014. e-Pub 2014.
171. William BM, de Lima M, Oran B, Champlin R, Papadopoulos EB, Giralt S, Scott BL, Hetzer J, Wang X, Laille E, Skikne BS, Craddock C. CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Blood 2014 ASH Annual Meeting 124(21):990, 2014. e-Pub 2014.
172. Ahmed S, Shpall EJ, Gulbis A, Jones R, Martinez CS, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat UR, Alousi AM, ieto Y, Hosing CM, Bashir Q, Kebriaei P, Qazilbash MH, Champlin RE, Mulanovich VE. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 2014 ASH Annual Meeting 124(21):1187, 2014. e-Pub 2014.
173. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. J Clin Oncol 2014 ASCO Annual Meeting 32(15_suppl):8601, 2014. e-Pub 2014.
174. Kongtim P, Pingali SR, Jimenez AM, Rondon G, Chen J, Oran B, Kebriaei P, Hamerstrom A, Ferro R, Lombardi L, Korbling M, Popat UR, Parmar S, Lee DA, Cooper L, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy) and melphalan-based conditioning: A retrospective analysis of the first 100 patients treated at MD Anderson Cancer Center. J Clin Oncol 2014 ASCO Annual Meeting 32(15_suppl):7017, 2014. e-Pub 2014.
175. Pingali SR, Milton D, di Stasi A, Patel RD, Kebriaei P, Popat UR, Alousi AM, Anderlini P, Qazilbash MH, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S40-S41, 2014. e-Pub 2014.
176. Adekola K, di Stasi A, Ferro R, Ahmed S, de Lima MJG, Oran B, Andersson BS, Quintas-Cardama A, Jabbour E, Kantarjian H, Cortes J, Champlin RE, Ciurea SO. Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S213-S214, 2014. e-Pub 2014.
177. Ghantoji SS, Goddu S, Sreenivasula S, Shah DP, Oran B, Rezvani K, Rondon G, Shpall EJ, Chemaly RF. Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S223-S224, 2014. e-Pub 2014.
178. Aung FM, Lichtiger B, Alousi A, Ahmed S, Anderlini P, Andersson BS, Bashir Q, Ciurea SO, Jones RB, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash MH, Shah N, Khouri I, Shpall EJ, Champlin RE, Popat UR. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. Blood 2013 ASH Annual Meeting 122(21):5449, 2013. e-Pub 2013.
179. Pingali SR, Denai M, Di Stasi A, Kebriaei P, Popat UR, Alousi A, Anderlini P, Parmar S, Hosing CM, Andersson BS, Bashir Q, Ahmed S, Oran B, Shpall EJ, Khouri I, Konopleva M, Alatrash G, Champlin RE, Ciurea SO. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 2013 ASH Annual Meeting 122(21):4523, 2013. e-Pub 2013.
180. Kongtim P, Popat UR, de Lima M, Garcia-Manero G, Jabbour EJ, Chen J, Rondon G, Abruzzo LV, Ciurea SO, Shpall EJ, Champlin RE, Oran B. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood 2013 ASH Annual Meeting 122(21):3340, 2013. e-Pub 2013.
181. Ghobadi A, Hamdi A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea SO, Oran B, Khouri I, Parmar S, Qazilbash MH, Kebriaei P, Popat UR, Rezvani K, Chemaly RF, Shpall EJ, Champlin RE, Bashir Q. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 2013 ASH Annual Meeting 122(21):4531, 2013. e-Pub 2013.
182. Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 2013 ASH Annual Meeting 122(21):691, 2013. e-Pub 2013.
183. Nusrat M, Kazmi SM, Cornelison AM, Kebriaei P, Nieto Y, Oran B, Orlowski RZ, Parmar S, Popat UR, Shah JJ, Shah N, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 2013 ASH Annual Meeting 122(21):3358, 2013. e-Pub 2013.
184. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, JOnes RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat UR. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 2013 ASH Annual Meeting 122(21):2083, 2013. e-Pub 2013.
185. Khouri IF, Saliba RM, Challagundia P, Ledesma C, Korbling M, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea SO, Hosing CM, Kebriaei P, Popat UR, Jabbour E, Champlin RE, Jorgensen JL. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 2013 ASH Annual Meeting 122(21):3349, 2013. e-Pub 2013.
186. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, de Lima M, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 2013 ASH Annual Meeting 122(21):2142, 2013. e-Pub 2013.
187. Oran B, Kongtim P, de Lima M, Popat UR, Garcia-Manero G, Jabbour EJ, Abruzzo LV, Chen J, Rondon G, Andersson BS, Alousi A, Ciurea SO, Shpall EJ, Champlin RE. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood 2013 ASH Annual Meeting 122(21):305, 2013. e-Pub 2013.
188. Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 2013 ASH Annual Meeting 122(21):3886, 2013. e-Pub 2013.
189. Khouri IF, Wei W, Valverde R, Korbling M, Turturro F, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea SO, Hosing CM, Popat UR, Jabbour E, Champlin RE, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 2013 ASH Annual Meeting 122(21):541, 2013. e-Pub 2013.
190. Di Stasi A, Poon LM, Ferro R, Milton D, Rondon G, Wang SA, Hamdi A, Qazilbash MH, Ahmed S, Khouri I, Oran B, Hosing CM, Kebriaei P, Alousi A, Popat UR, Shpall EJ, Lee DA, Rezvani K, Champlin RE, Ciurea SO. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 2013 ASH Annual Meeting 122(21):2167, 2013. e-Pub 2013.
191. Jimenez AM, De Lima M, Popat UR, Borthakur G, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chen J, Bashir Q, Ciurea SO, Kebriaei P, Ahmed S, Khouri IF, Kongtim P, Qazilbash MH, Rondon G, Shpall EJ, Champlin RE, Oran B. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). J Clin Oncol 2013 ASCO Annual Meeting 31(15_suppl):7010, 2013. e-Pub 2013.
192. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima M, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. J Clin Oncol 2013 ASCO Annual Meeting 31(15_suppl):7011, 2013. e-Pub 2013.
193. Bejanyan N, Oran B, Shanley R, Ustun C, Warlick E, Verneris MR, Wagner JE, Weisdorf DJ, Brunstein CG. Similar Survival in Patients with Acute Myeloid Leukemia Relapsing After Matched Related Donor and Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplement):S113, 2013. e-Pub 2013.
194. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, De Lima M, Andersson BS, Kebriaei P, Oran B, Champlin RE. Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS. Blood 2012 ASH Annual Meeting 120(21):3075, 2012. e-Pub 2012.
195. Jabbour EJ, Kantarjian H, Oran B, Ravandi F, Ghanem H, Khouri I, Garcia-Manero G, Mathisen MS, Bashir Q, Saliba RM, Khouri M, Pierce SA, Brandt M, Champlin RE, De Lima M. Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood 2012 ASH Annual Meeting 120(21):2029, 2012. e-Pub 2012.
196. Altin H, Karatas Z, Sap F, Alp H, Baysal T, Karaaslan S, Oran B. Sol-sag santli dogustan kalp hastaligi olan cocuklarda pulmoner arteriyel hipertansiyonla malnutrisyonun iliskisi: Gozlemsel bir calisma. Anadolu Kardiyol Derg 12(2):150-9, 2012. e-Pub 2012. PMID: 22306568.
197. Oran B, Weisdorf DJ, Virnig B. A Population-Based Study In Acute Myeloid Leukemia (AML) Suggests Improved Overall Survival (OS) up to Age 80 with Intravenous Therapy: 2000–2007 Data From the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry In the United States (US),. Blood 2011 ASH Annual Meeting 118(21):3589, 2011. e-Pub 2011.
198. Oran B, Singleton T, Ramirez PA, Shanley R, Brunstein C, Ustun C, Warlick ED, Weisdorf DJ. Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of Minimal Residual Disease in Acute Myeloid Leukemia. Blood 2011 ASH Annual Meeting 118(21):2027, 2011. e-Pub 2011.
199. Majhail NS, Brunstein CG, Warlick ED, Oran B, Shanley R, Sandhu KS, Wagner JE, Weisdorf DJ. Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: Comparable Outcomes With Unrelated Umbilical Cord Blood and HLA-Identical Sibling Donors. Biol Blood Marrow Transplant 2011 BMT Meetings 17(2, Supplement):S155, 2011. e-Pub 2011.
200. Oran B, Wagner JE, Defor T, Weisdorf DJ, Brunstein C. Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. Blood 2010 ASH Annual Meeting 116(21):3531, 2010. e-Pub 2010.
201. Oran B, Quing C, Brunstein C, Majhail N, Weisdorf D. Similar And Promising Outcomes In Older AML Patients In First Complete Remission After Reduced Intensity Conditioning With Cord Blood And Sibling Donor Transplantation. Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(Supplement 2):S231-S232, 2010. e-Pub 2010.
202. Oran B, Dolan M, Ma L, Brunstein C, Warlick E, Weisdorf DJ. Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients. Blood 2009 ASH Annual Meeting 114(22):525, 2009. e-Pub 2009.
203. Rosenzweig MA, Seldin DC, Remick D, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile Reactions Occurring With Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis: A “Melphalan Recall” Reaction. Biol Blood Marrow Transplant 2009 BMT Meetings 15(2, Supplement):40, 2009. e-Pub 2009.
204. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with a second cycle of high dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction. Blood 2008 ASH Annual Meeting 112(11):1120, 2008. e-Pub 2008.
205. van Besien K, de Lima M, Artz A, Oran B, Stock W, Giralt S. Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS. Blood 2007 ASH Annual Meeting 110(11):1076, 2007. e-Pub 2007.
206. Saliba RM, Komanduri K, Giralt S, de Souza J, Patah PA, Oran B, Rondon G, Couriel DP, Champlin R, de Lima M. Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML. Biol Blood Marrow Transplant 2009 BMT Meetings 13(2, Supplement):98, 2007. e-Pub 2007.
207. Seldin DC, Skinner M, Oran B, Quillen K, Finn KT, Sanchorawala V. Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). Blood 2006 ASH Annual Meeting 108(11):3094, 2006. e-Pub 2006.
208. Saliba RM, Oran B, Giralt S, Komanduri K, Carrasco-Yalan A, Ghosh S, Champlin R, de Lima M. Disease status at transplant impacts lymphocyte and platelet recovery after allogeneic peripheral blood stem cell transplant (PBSCT) for patients with AML/MDS. Biol Blood Marrow Transplant 2006 BMT Meetings 12(2, Supplement):42, 2006. e-Pub 2006.
209. Oran B, Aleman A, Shpall EJ, Hosing C, Korbling M, Anderlini P, Champlin R, Donato M. Higher Rate of Thrombotic Thrombocytopenic Pupura (TTP) Associated with Graft Versus Host Disease (GVHD) and Unrelated Donor Bone Marrow Transplantation (BMT). Blood 2005 ASH Annual Meeting 106(11):1111, 2005. e-Pub 2005.
210. Oran B, Hun L, de Lima M, Couriel D, MD, Giralt S, Saliba R. Steroid complications in patiensts with acute graft versus host disease. Blood 2005 ASH Annual Meeting 106(11):5338, 2005. e-Pub 2005.
211. Oran B, Giralt S, Shahjahan M, Anagnostopoulos A, Couriel D, Kebriaei P, Hosing C, Ghosh S, D Meis E, Donato M, Ativivas T, Carrasco-Yalan A, Champlin R, de Lima M. Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens. Blood 2005 ASH Annual Meeting 106(11):2019, 2005. e-Pub 2005.
212. Oran B, Saliba R, Giralt G, Couriel D, Carrasco-Yalan A, Hosing C, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Ghosh S, Khouri I, Champlin R, de Lima M. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS. Blood 2005 ASH Annual Meeting 106(11):838, 2005. e-Pub 2005.
213. Finn KT, Sanchorawala V, Kunz R, Seldin D, Wilkes G, Oran B. Cryotherapy (ice chips) is effective in preventing melphalan-induced oral mucositis (OM) in patients with AL amyloidosis. Biol Blood Marrow Transplant 2004 BMT Meetings 10(Supplement 1):86, 2004. e-Pub 2004.

Book Chapters

1. Oran, B. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients, 263-277, 2023.
2. Rafei, H, Mehta, RS, Oran, B, Rezvani, K, Shpall, E, Olson, AL. Umbilical Cord Blood Transplantation, 101-114, 2023.
3. Oran B. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients. In: In: Manual of Stem Cell Transplantation and Cellular Therapies for Hematologic Malignancies. First Edition. Elsevier Books, 2022.
4. Mehta R, Oran B, Shpall E. Alternative Donor Transplant: Cord Blood Transplant. In: The M.D. Anderson Manual of Medical Oncology, 3rd Edition. McGraw Hill, 2015.

Letters to the Editor

1. Tokgoz H, Oran B, Aydin K. Reply from the authors of the article entitled "Importance of accurate measurement of carotid intima media thickness for evaluating epileptic children treated with valproate". Childs Nerv Syst 29: 357, 2013.
2. Unal E, Yazar A, Oran B. The importance of troponin-I as a predictor of cardiac injury caused by carbon monoxide poisoning. Inhal Toxicol 19: 587; author reply 589, 2007.